抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

https://caltcm.memberclicks.net/assets/documents/acc_aha_chf_2013_guidelines.pdf

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.

Standards of Medical Care in Diabetes

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

[Telemedicine in acute stroke care: current status and developments].

Die Evaluation von Stroke Units als medizinische Technologie

Thrombolytic therapy with rt-PA given within 3 h after stroke onset to patients with ischemic stroke significantly improves outcome after stroke. There are some evidences that thrombolysis may also work up to 6 h after stroke onset in carefully identified patients, but the three most important trials, which used 0-6 h time-windows, combined with CT-scans to define the ischemic areas, failed individually to produce statistical benefits for the rt-PA-treated patients. In order to enlarge the time-window there is a need for additional information about the functionality of the affected brain area. There is a growing interest in the use of Diffusion Weighted (magnetic resonance) imaging (DWI) and Perfusion Weighted (magnetic resonance) imaging (PWI) in the assessment of patients with acute ischemic stroke. These magnetic resonance techniques are powerful methods for identifying the extent and location of early cerebral ischemia.

Werner Hacke

Papers

[Telemedicine in acute stroke care: current status and developments].

Die Evaluation von Stroke Units als medizinische Technologie

The very acute stroke treatment: fibrinolysis and after

3-33-01 Lubeluzole in acute ischemic stroke: International trial

Hemicraniectomy for middle-cerebral-artery stroke. Author reply.